Breaking News

Lantern Pharma Launches ADC Program

Will leverage RADR artificial intelligence platform to target solid tumors and blood cancers through agreement with Califia Pharma.

By: Contract Pharma

Contract Pharma Staff

Lantern Pharma, a clinical-stage biopharma company using its RADR artificial intelligence platform to advance cancer drug development, is launching the development of its ADC (Antibody Drug Conjugate) program through an evaluation and potential development agreement with Califia Pharma, along with other key internal development and computational initiatives.   Lantern will leverage the linker library, conjugation processes and payloads, including its own DNA damage causing compounds, LP-100 an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters